Anti-PHAG1/ PAG1/ CBP monoclonal antibody
Anti-PHAG1/ PAG1/ CBP antibody for FACS & in-vivo assay
Go to PAG1/PAG1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP1310-Ab-1/ GM-Tg-hg-MP1310-Ab-2 | Anti-Human PAG1 monoclonal antibody | Human |
| GM-Tg-rg-MP1310-Ab-1/ GM-Tg-rg-MP1310-Ab-2 | Anti-Rat PAG1 monoclonal antibody | Rat |
| GM-Tg-mg-MP1310-Ab-1/ GM-Tg-mg-MP1310-Ab-2 | Anti-Mouse PAG1 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP1310-Ab-1/ GM-Tg-cynog-MP1310-Ab-2 | Anti-Cynomolgus/ Rhesus macaque PAG1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP1310-Ab-1/ GM-Tg-felg-MP1310-Ab-2 | Anti-Feline PAG1 monoclonal antibody | Feline |
| GM-Tg-cang-MP1310-Ab-1/ GM-Tg-cang-MP1310-Ab-2 | Anti-Canine PAG1 monoclonal antibody | Canine |
| GM-Tg-bovg-MP1310-Ab-1/ GM-Tg-bovg-MP1310-Ab-2 | Anti-Bovine PAG1 monoclonal antibody | Bovine |
| GM-Tg-equg-MP1310-Ab-1/ GM-Tg-equg-MP1310-Ab-2 | Anti-Equine PAG1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP1310-Ab-1/ GM-Tg-hg-MP1310-Ab-2; GM-Tg-rg-MP1310-Ab-1/ GM-Tg-rg-MP1310-Ab-2; GM-Tg-mg-MP1310-Ab-1/ GM-Tg-mg-MP1310-Ab-2; GM-Tg-cynog-MP1310-Ab-1/ GM-Tg-cynog-MP1310-Ab-2; GM-Tg-felg-MP1310-Ab-1/ GM-Tg-felg-MP1310-Ab-2; GM-Tg-cang-MP1310-Ab-1/ GM-Tg-cang-MP1310-Ab-2; GM-Tg-bovg-MP1310-Ab-1/ GM-Tg-bovg-MP1310-Ab-2; GM-Tg-equg-MP1310-Ab-1/ GM-Tg-equg-MP1310-Ab-2 |
| Products Name | Anti-PAG1 monoclonal antibody |
| Format | mab |
| Target Name | PAG1 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-PAG1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species PHAG1/ PAG1/ CBP VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | pGMLPm005425 | mouse Pag1 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm005425 | mouse Pag1 Lentivirus particle |
Target information
| Target ID | GM-MP1310 |
| Target Name | PAG1 |
| Gene ID | 55824,94212,64019,700748,610895,101086450,614460,100050548 |
| Gene Symbol and Synonyms | CBP,F730007C19Rik,PAG,PAG1 |
| Uniprot Accession | Q9NWQ8,Q9JM80 |
| Uniprot Entry Name | PHAG1_HUMAN,PHAG1_RAT |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000076641 |
| Target Classification | N/A |
The target: PAG1, gene name: PAG1, also named as CBP, PAG. The protein encoded by this gene is a type III transmembrane adaptor protein that binds to the tyrosine kinase csk protein. It is thought to be involved in the regulation of T cell activation. [provided by RefSeq, Jul 2008].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

